ClinicalTrials.gg
CompletedNCT06280716Updated Oct 16, 2026Results posted

A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

A Phase 3 interventional study of Placebo and Lebrikizumab in Atopic Dermatitis, sponsored by Eli Lilly and Company. Completed at 46 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Updated Oct 16, 2026Now CompletedResults posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
301
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.

Enrollment
8th of 24
301 · median 252
Started
2024
with 1 other
Phase 3
17 of 24
2 open now
Registered
18th of 24
by date
Lead sponsor
14 of 24
Eli Lilly and Company

Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 8th largest by enrollment, is one of 2 that started in 2024, is one of 17 in phase 3, and was the 18th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing lebrikizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis. The study will last approximately 62 weeks.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have chronic AD that has been present for ≥1 year before the screening period or have chronic eczema and meet the AAD criteria.
  • Have moderate-to-severe AD, including all of the following at the baseline: EASI score ≥16, IGA score ≥3 (scale of 0 to 4), ≥10% BSA of AD involvement.
  • Have a documented history provided by a physician and/or investigator of inadequate response to existing topical medications within 6 months preceding screening as defined by at least 1 of the following:

    1. Inability to achieve good disease control, defined as mild disease or better after use of at least a medium-potency TCS for at least 4 weeks, or for the maximum duration recommended by the product prescribing information, whichever is shorter. TCS may be used with or without TCIs and/or topical Janus kinase (JAK) inhibitors.
    2. Participants who failed systemic therapies intended to treat AD within 6 months preceding screening, such as cyclosporine, MTX, azathioprine, and MMF, will also be considered as surrogates for having inadequate response to topical therapy.
  • Adolescents body weight must be ≥40 kg at baseline.
  • Males may participate in this trial and comply with specific local government study requirements. Females of and females not of childbearing potential may participate in this trial.

Exclusion criteria

Exclusion Criteria:

  • Have received a dose of lebrikizumab in any prior lebrikizumab clinical study.
  • Have a history of anaphylaxis or uncontrolled chronic disease that might require bursts of oral .
  • Have a current or recent acute, active infection. For at least 30 days before screening and up to the randomization, participants must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment.
  • Have had Serious, Opportunistic, Chronic and Recurring infection within 3 months prior to the screening or develops any of these infections before the randomization.
  • Have active tuberculosis (TB) or latent tuberculosis infection (LTBI) that has not been treated with a complete course of appropriate therapy or such treatment is underway.
  • Have a current infection with , , (HIV) infection.
  • Have presence of skin comorbidities that may interfere with study assessments.
  • Have a diagnosis or history of malignant disease within 5 years before screening, with the following exceptions:

    1. basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years, and
    2. cervical carcinoma in situ, with no evidence of recurrence within 5 years before screening visit.
  • Pregnant or breastfeeding women or women planning to become pregnant or breastfeed during the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
301 participants (actual)

Study arms

  • Placebo comparator
    Combo Cohort: Placebo + TCS

    Participants received Placebo injection subcutaneously administered every 2 weeks (Q2W) in combination with topical corticosteroid (TCS) up to Week 16.

    Drug: Placebo · Drug: Topical Corticosteroid

  • Experimental
    Combo Cohort: 250 mg Lebrikizumab + TCS

    Participant received 250 mg (milligrams) Lebrikizumab injection subcutaneously administered Q2W in combination with TCS up to Week 16.

    Drug: Lebrikizumab

  • Experimental
    Mono Cohort: 250 mg Lebrikizumab

    Participant received 250 mg Lebrikizumab injection subcutaneously administered Q2W up to Week 16.

    Drug: Lebrikizumab

  • Placebo comparator
    Mono Cohort: Placebo

    Participant received Placebo injection subcutaneously administered Q2W up to Week 16.

    Drug: Placebo

Interventions

  • DrugPlacebo

    Subcutaneous injection

  • Subcutaneous injection

    Also known as: LY3650150

  • DrugTopical Corticosteroid

    Topical Corticosteroid

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Eczema Area and Severity Index (EASI)-75 (≥75% Reduction From Baseline in EASI Score) at Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)

    EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity. The EASI-75 responder is defined as a participant who achieves a ≥ 75% reduction from baseline in the EASI score.

    Time frame: Week 16

  2. Percentage of Participants With a Response of Investigator Global Assessment (IGA) Score 0 or 1 and a Reduction of ≥2 Points From Baseline to Week 16 (Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab)

    The IGA measures the investigator's global assessment of the participant's overall severity of their Atopic Dermatitis. The IGA is comprised of a 5-point numeric scale ranging from 0 (clear skin) to 4 (severe disease) and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Percentage of Participants Achieving Response of Eczema Area and Severity Index (EASI)-90 (≥90% Reduction From Baseline in EASI Score) at Week 16 (Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab)

    EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity. The EASI-90 responder is defined as a participant who achieves a ≥ 90% reduction from baseline in the EASI score.

    Time frame: Week 16

  2. Percentage of Participants Who Achieved a ≥4 Point Improvement in Itch Numerical Rating Scale (NRS) Score at Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)

    Percentage of Participants who Achieved a ≥4 Point improvement in Itch NRS Score at Week 16 is reported. The Itch NRS is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

    Time frame: Week 16

  3. Percent Change From Baseline in Itch Numeric Rating Scale (NRS) (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)

    The Itch NRS is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable". LS mean was calculated using MMRM model which includes: treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit, age group, baseline IGA score and country.

    Time frame: Baseline, Week 16

  4. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)

    The DLQI questionnaire is a 10-item, quality-of-life questionnaire (for participants \>=16 years) that covers 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, treatment) to assess impact of skin disease on the quality of life of an affected person. The recall period of this scale is over the "last week." Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively, and unanswered (or "not relevant") responses scored as 0. Questions are scored from 0 to 3, giving possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life. LS mean was calculated using MMRM model which includes :treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit, age group, baseline IGA score and country.

    Time frame: Baseline, Week 16

  5. Percent Change From Baseline in Total Eczema Area and Severity Index (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)

    EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity.

    Time frame: Baseline, Week 16

07

Results

Posted Oct 16, 2026

Participant flow

Participant flow — Overall Study
MilestoneCombo Cohort: Placebo + TCSCombo Cohort: 250 mg Lebrikizumab + TCSMono Cohort: PlaceboMono Cohort: 250 mg Lebrikizumab
Started561124489
Completed21335
Not completed54994184
Withdrew: Withdrawal by parent/guardian0110
Withdrew: Withdrawal by subject51525
Withdrew: Lost to follow-up0001
Withdrew: Lack of efficacy0111
Withdrew: Adverse event2222
Withdrew: Other0100
Withdrew: Protocol deviation0200
Withdrew: Ongoing47773575

Outcome measures

PrimaryPercentage of Participants Achieving Eczema Area and Severity Index (EASI)-75 (≥75% Reduction From Baseline in EASI Score) at Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)

EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity. The EASI-75 responder is defined as a participant who achieves a ≥ 75% reduction from baseline in the EASI score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Eczema Area and Severity Index (EASI)-75 (≥75% Reduction From Baseline in EASI Score) at Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)
percentage of participantsCombo Cohort: Placebo + TCSCombo Cohort: 250 mg Lebrikizumab + TCSMono Cohort: PlaceboMono Cohort: 250 mg Lebrikizumab
Percentage of Participants Achieving Eczema Area and Severity Index (EASI)-75 (≥75% Reduction From Baseline in EASI Score) at Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)37.857.518.551.7
Statistical analysis
  • Combo Cohort: Placebo + TCS vs Combo Cohort: 250 mg Lebrikizumab + TCS · Bayesian hierarchical model · Posterior mean response difference: 22.0 · 90% CI 9.3 to 33.2
  • Mono Cohort: Placebo vs Mono Cohort: 250 mg Lebrikizumab · Risk difference (rd): 32.1 · 95% CI 17.6 to 46.5
PrimaryPercentage of Participants With a Response of Investigator Global Assessment (IGA) Score 0 or 1 and a Reduction of ≥2 Points From Baseline to Week 16 (Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab)

The IGA measures the investigator's global assessment of the participant's overall severity of their Atopic Dermatitis. The IGA is comprised of a 5-point numeric scale ranging from 0 (clear skin) to 4 (severe disease) and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point.

Time frame:
Baseline, Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Response of Investigator Global Assessment (IGA) Score 0 or 1 and a Reduction of ≥2 Points From Baseline to Week 16 (Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab)
percentage of participantsCombo Cohort: Placebo + TCSCombo Cohort: 250 mg Lebrikizumab + TCSMono Cohort: PlaceboMono Cohort: 250 mg Lebrikizumab
Percentage of Participants With a Response of Investigator Global Assessment (IGA) Score 0 or 1 and a Reduction of ≥2 Points From Baseline to Week 16 (Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab)17.225.07.127.0
Statistical analysis
  • Combo Cohort: Placebo + TCS vs Combo Cohort: 250 mg Lebrikizumab + TCS · Bayesian hierarchical model · Posterior mean response difference: 8.3 · 90% CI -2.1 to 17.1
  • Mono Cohort: Placebo vs Mono Cohort: 250 mg Lebrikizumab · Risk difference (rd): 19.7 · 90% CI 7.8 to 31.5
SecondaryPercentage of Participants Achieving Response of Eczema Area and Severity Index (EASI)-90 (≥90% Reduction From Baseline in EASI Score) at Week 16 (Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab)

EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity. The EASI-90 responder is defined as a participant who achieves a ≥ 90% reduction from baseline in the EASI score.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Response of Eczema Area and Severity Index (EASI)-90 (≥90% Reduction From Baseline in EASI Score) at Week 16 (Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab)
percentage of participantsCombo Cohort: Placebo + TCSCombo Cohort: 250 mg Lebrikizumab + TCSMono Cohort: PlaceboMono Cohort: 250 mg Lebrikizumab
Percentage of Participants Achieving Response of Eczema Area and Severity Index (EASI)-90 (≥90% Reduction From Baseline in EASI Score) at Week 16 (Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab)19.133.911.530.3
Statistical analysis
  • Combo Cohort: Placebo + TCS vs Combo Cohort: 250 mg Lebrikizumab + TCS · Risk difference (rd): 14.4 · 95% CI 0.8 to 27.9
  • Mono Cohort: Placebo vs Mono Cohort: 250 mg Lebrikizumab · Risk difference (rd): 18.0 · 95% CI 4.9 to 31.1
SecondaryPercentage of Participants Who Achieved a ≥4 Point Improvement in Itch Numerical Rating Scale (NRS) Score at Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)

Percentage of Participants who Achieved a ≥4 Point improvement in Itch NRS Score at Week 16 is reported. The Itch NRS is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a ≥4 Point Improvement in Itch Numerical Rating Scale (NRS) Score at Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)
percentage of participantsCombo Cohort: Placebo + TCSCombo Cohort: 250 mg Lebrikizumab + TCSMono Cohort: PlaceboMono Cohort: 250 mg Lebrikizumab
Percentage of Participants Who Achieved a ≥4 Point Improvement in Itch Numerical Rating Scale (NRS) Score at Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)19.531.722.141.0
Statistical analysis
  • Combo Cohort: Placebo + TCS vs Combo Cohort: 250 mg Lebrikizumab + TCS · Risk difference (rd): 10.8 · 95% CI -4.1 to 25.8
  • Mono Cohort: Placebo vs Mono Cohort: 250 mg Lebrikizumab · Risk difference (rd): 19.2 · 95% CI 3.0 to 35.4
SecondaryPercent Change From Baseline in Itch Numeric Rating Scale (NRS) (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)

The Itch NRS is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable". LS mean was calculated using MMRM model which includes: treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit, age group, baseline IGA score and country.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Itch Numeric Rating Scale (NRS) (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)
Percent changeCombo Cohort: Placebo + TCSCombo Cohort: 250 mg Lebrikizumab + TCSMono Cohort: PlaceboMono Cohort: 250 mg Lebrikizumab
Percent Change From Baseline in Itch Numeric Rating Scale (NRS) (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)-29.40 ± 5.13-41.19 ± 3.60-19.57 ± 9.83-41.97 ± 6.65
Statistical analysis
  • Combo Cohort: Placebo + TCS vs Combo Cohort: 250 mg Lebrikizumab + TCS · Mixed Models Analysis · Least squares mean difference: -11.80 · 95% CI -23.84 to 0.25
  • Mono Cohort: Placebo vs Mono Cohort: 250 mg Lebrikizumab · Mixed Models Analysis · Least squares mean difference: -22.41 · 95% CI -45.46 to 0.65
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)

The DLQI questionnaire is a 10-item, quality-of-life questionnaire (for participants \>=16 years) that covers 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, treatment) to assess impact of skin disease on the quality of life of an affected person. The recall period of this scale is over the "last week." Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively, and unanswered (or "not relevant") responses scored as 0. Questions are scored from 0 to 3, giving possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life. LS mean was calculated using MMRM model which includes :treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit, age group, baseline IGA score and country.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)
score on a scaleCombo Cohort: Placebo + TCSCombo Cohort: 250 mg Lebrikizumab + TCSMono Cohort: PlaceboMono Cohort: 250 mg Lebrikizumab
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)-4.45 ± 0.800-5.75 ± 0.563-2.92 ± 0.926-6.01 ± 0.704
Statistical analysis
  • Combo Cohort: Placebo + TCS vs Combo Cohort: 250 mg Lebrikizumab + TCS · Mixed Models Analysis · Least squares mean difference: -1.30 · 95% CI -3.2 to 0.6
  • Mono Cohort: Placebo vs Mono Cohort: 250 mg Lebrikizumab · Mixed Models Analysis · Least squares mean difference: -3.09 · 95% CI -5.2 to -1.0
SecondaryPercent Change From Baseline in Total Eczema Area and Severity Index (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)

EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Total Eczema Area and Severity Index (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)
Percent changeCombo Cohort: Placebo + TCSCombo Cohort: 250 mg Lebrikizumab + TCSMono Cohort: PlaceboMono Cohort: 250 mg Lebrikizumab
Percent Change From Baseline in Total Eczema Area and Severity Index (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)-58.75 ± 5.121-69.44 ± 3.825-30.25 ± 6.373-60.12 ± 5.039
Statistical analysis
  • Combo Cohort: Placebo + TCS vs Combo Cohort: 250 mg Lebrikizumab + TCS · Mixed Models Analysis · Least squares mean difference: -10.69 · 95% CI -21.9 to 0.5
  • Mono Cohort: Placebo vs Mono Cohort: 250 mg Lebrikizumab · Mixed Models Analysis · Least squares mean difference: -29.88 · 95% CI -41.9 to -17.9

Adverse events

Collected over Baseline up to week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combo Cohort: Placebo + TCS0/56 (0%)1/56 (1.8%)26/56 (46.4%)
Combo Cohort: 250 mg Lebrikizumab + TCS0/112 (0%)3/112 (2.7%)31/112 (27.7%)
Mono Cohort: Placebo0/44 (0%)1/44 (2.3%)14/44 (31.8%)
Mono Cohort: 250 mg Lebrikizumab0/89 (0%)0/89 (0%)31/89 (34.8%)
Most frequent serious events
Most frequent serious events
EventCombo Cohort: Placebo + TCSCombo Cohort: 250 mg Lebrikizumab + TCSMono Cohort: PlaceboMono Cohort: 250 mg Lebrikizumab
Humerus fractureInjury, poisoning and procedural complications0/560/1121/440/89
Herpes zosterInfections and infestations1/560/1120/440/89
AppendicitisInfections and infestations0/561/1120/440/89
Post herpetic neuralgiaNervous system disorders0/561/1120/440/89
Pleural effusionRespiratory, thoracic and mediastinal disorders0/561/1120/440/89
PleurisyRespiratory, thoracic and mediastinal disorders0/561/1120/440/89
Most frequent other events
Most frequent other events
EventCombo Cohort: Placebo + TCSCombo Cohort: 250 mg Lebrikizumab + TCSMono Cohort: PlaceboMono Cohort: 250 mg Lebrikizumab
Upper respiratory tract infectionInfections and infestations9/569/1126/445/89
Alanine aminotransferase increasedInvestigations3/565/1124/445/89
Blood creatine phosphokinase increasedInvestigations4/562/1121/445/89
Aspartate aminotransferase increasedInvestigations3/564/1123/442/89
ConjunctivitisInfections and infestations3/566/1120/446/89
Injection site reactionGeneral disorders2/563/1120/445/89
Skin infectionInfections and infestations3/561/1120/440/89
Blood lactate dehydrogenase increasedInvestigations3/561/1122/443/89
HyperuricaemiaMetabolism and nutrition disorders3/566/1122/443/89

Baseline characteristics

All Randomized participants.

Age, Categorical
Age, Categorical(Participants)Combo Cohort: Placebo + TCSCombo Cohort: 250 mg Lebrikizumab + TCSMono Cohort: PlaceboMono Cohort: 250 mg LebrikizumabTotal
<=18 years122471457
Between 18 and 65 years38763272218
>=65 years6125326
Sex: Female, Male
Sex: Female, Male(Participants)Combo Cohort: Placebo + TCSCombo Cohort: 250 mg Lebrikizumab + TCSMono Cohort: PlaceboMono Cohort: 250 mg LebrikizumabTotal
Female17362028101
Male39762461200
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Combo Cohort: Placebo + TCSCombo Cohort: 250 mg Lebrikizumab + TCSMono Cohort: PlaceboMono Cohort: 250 mg LebrikizumabTotal
Hispanic or Latino00000
Not Hispanic or Latino47993985270
Unknown or Not Reported9135431
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Combo Cohort: Placebo + TCSCombo Cohort: 250 mg Lebrikizumab + TCSMono Cohort: PlaceboMono Cohort: 250 mg LebrikizumabTotal
American Indian or Alaska Native00000
Asian561124489301
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
08

Study locations

46 sites
  • Wannan Medical College Yijishan Hospital
    Wuhu, Anhui 241001, China
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality 100029, China
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100034, China
  • Beijing Children's hospital, Capital Medical University
    Beijing, Beijing Municipality 100045, China
  • Beijing Friendship Hospital Affiliate of Capital University
    Beijing, Beijing Municipality 100050, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100091, China
  • Beijing Tongren Hospital affiliated to Capital Medical University
    Beijing, Beijing Municipality 100730, China
  • Beijing Tsinghua Changgung Hospital
    Beijing, Beijing Municipality 102202, China
  • The Children's Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400065, China
  • Zhongshan Hospital Fudan University (Xiamen Branch)
    Xiamen, Fujian 361015, China
  • Guangdong Province Dermatology Hospital
    Guangzhou, Guangdong 510018, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510180, China
  • Shenzhen Children's Hospital
    Shenzhen, Guangdong 518026, China
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
  • The University of Hong Kong-Shenzhen Hospital
    Shenzhen, Guangdong 518053, China
  • Hainan General Hospital
    Haikou, Hainan 570311, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050031, China
  • The First Hospital of Wuhan
    Wuhan, Hubei 430022, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • Hunan Children's Hospital
    Changsha, Hunan 410007, China
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • Wuxi No.2 People's Hospital
    Wuxi, Jiangsu 214000, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212000, China
  • The Second Hospital of Jilin University
    Changchun, Jilin 130000, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710004, China
  • Shanghai Sixth People's Hospital
    Shanghai, Shanghai Municipality 200030, China
  • Huashan Hospital, Fudan University
    Shanghai, Shanghai Municipality 200040, China
  • Shanghai Tenth People's Hospital
    Shanghai, Shanghai Municipality 200072, China
  • Children's Hospital of Shanxi
    Taiyuan, Shanxi 030013, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300052, China
  • The First People's Hospital of Hangzhou
    Hangzhou, Zhejiang 310000, China
  • The first Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Zhejiang University School of Medicine - The Fourth Affiliated Hospital
    Yiwu, Zhejiang 322000, China
  • The First Affiliated Hospital Of Fujian Medical University
    Fuzhou, 350005, China
  • Shanghai Skin Disease Hospital
    Shanghai, 200071, China
  • The Catholic University of Korea, Incheon St. Mary's Hospital
    Bupyeong-gu, Incheon-gwangyeoksi [Incheon] 21431, South Korea
  • Korea University Ansan Hospital
    Ansan-si, Kyǒnggi-do 15355, South Korea
  • National Medical Center
    Seoul, Seoul-teukbyeolsi [Seoul] 01812, South Korea
  • Asan Medical Center
    Seoul, Seoul-teukbyeolsi [Seoul] 05505, South Korea
  • Hallym University Kangnam Sacred Heart Hospital
    Seoul, Seoul-teukbyeolsi [Seoul] 07441, South Korea
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Sep 2025, 17 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 17 months is close to that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jul 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Feb 28, 2024
StartActual
Apr 24, 2024
Primary completionActual
Sep 25, 2025
CompletionActual
Jul 16, 2026was Aug 2026
Results first posted
Oct 16, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 16, 2026
Results
Results posted
posted Oct 16, 2026
Study completion
Aug 2026→Jul 16, 2026 (actual)
Oct 16, 2026
Interventions
Arms added: Combo Cohort: Placebo + TCS·Combo Cohort: 250 mg Lebrikizumab + TCS·Mono Cohort: 250 mg Lebrikizumab·Mono Cohort: Placebo; arms removed: Lebrikizumab every 2 weeks (Q2W)·Lebrikizumab every 4 weeks (Q4W)·Lebrikizumab every 8 weeks (Q8W)·Escape Arm (Lebrikizumab Q2W)·Placebo
Oct 16, 2026
Primary outcomes
2 edited, 2 removed
What changed in the outcomes
  • EditedPercentage of Participants Achieving Eczema Area and Severity Index (EASI)-75) (≥75% Reduction From Baseline in EASI Score) forat Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)Time frame: Week 16
  • EditedPercentage of Participants Achieving With a Response of Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction of ≥2 Points From Baseline to Week 16 for(Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab)Time frame: Baseline, Week 16
  • RemovedPercentage of Participants Achieving EASI-75 for Combo CohortTime frame: Week 16
  • RemovedPercentage of Participants Achieving IGA Score of 0 or 1 and a Reduction of ≥2 Points From Baseline to Week 16 for Combo CohortTime frame: Baseline, Week 16
Oct 16, 2026
Documents
Secondary outcomes
3 edited, 2 added, 7 removed
What changed in the outcomes
  • EditedPercentage of Participants Achieving Response of Eczema Area and Severity Index (EASI)-90 (≥90% Reduction From Baseline in EASI Score) for at Week 16 (Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab)Time frame: Week 16
  • EditedPercent Change fromFrom Baseline in Itch Numeric Rating Scale (NRS) for (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)Time frame: Baseline, Week 16
  • EditedChange fromFrom Baseline in Dermatology Life Quality Index (DLQI) for Total Score (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)Time frame: Baseline, Week 16
  • AddedPercentage of Participants Who Achieved a ≥4 Point Improvement in Itch Numerical Rating Scale (NRS) Score at Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)Time frame: Week 16
  • AddedPercent Change From Baseline in Total Eczema Area and Severity Index (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)Time frame: Baseline, Week 16
  • RemovedPercentage of Participants With a Itch Numerical Rating Scale (NRS) Score of ≥4-Points at Baseline who Achieve a ≥4-Point Reduction in Itch NRS Score From Baseline to Week 16 for Combo CohortTime frame: Baseline, Week 16
  • RemovedPercentage Change From Baseline in EASI Score for Combo CohortTime frame: Baseline, Week 16
  • RemovedPercentage of Participants Achieving EASI-90 for Mono CohortTime frame: Week 16
  • RemovedPercentage of Participants With a Itch NRS Score of ≥4-Points at Baseline who Achieve a ≥4-Point Reduction in Itch NRS Score From Baseline to Week 16 for Mono CohortTime frame: Baseline, Week 16
  • RemovedPercentage Change From Baseline in EASI Score for Mono CohortTime frame: Week 16
  • RemovedPercent Change from Baseline in Itch Numeric Rating Scale (NRS) for Mono CohortTime frame: Baseline, Week 16
  • RemovedChange from Baseline in Dermatology Life Quality Index (DLQI) for Mono CohortTime frame: Baseline, Week 16
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Active, not recruiting→Completed
    Results posted
    Study completion Aug 2026→Jul 16, 2026 (now actual)
    Primary outcomes 2 edited, 2 removed
    What changed in the outcomes
    • EditedPercentage of Participants Achieving Eczema Area and Severity Index (EASI)-75) (≥75% Reduction From Baseline in EASI Score) forat Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)Time frame: Week 16
    • EditedPercentage of Participants Achieving With a Response of Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction of ≥2 Points From Baseline to Week 16 for(Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab)Time frame: Baseline, Week 16
    • RemovedPercentage of Participants Achieving EASI-75 for Combo CohortTime frame: Week 16
    • RemovedPercentage of Participants Achieving IGA Score of 0 or 1 and a Reduction of ≥2 Points From Baseline to Week 16 for Combo CohortTime frame: Baseline, Week 16
    Secondary outcomes 3 edited, 2 added, 7 removed
    What changed in the outcomes
    • EditedPercentage of Participants Achieving Response of Eczema Area and Severity Index (EASI)-90 (≥90% Reduction From Baseline in EASI Score) for at Week 16 (Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab)Time frame: Week 16
    • EditedPercent Change fromFrom Baseline in Itch Numeric Rating Scale (NRS) for (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)Time frame: Baseline, Week 16
    • EditedChange fromFrom Baseline in Dermatology Life Quality Index (DLQI) for Total Score (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)Time frame: Baseline, Week 16
    • AddedPercentage of Participants Who Achieved a ≥4 Point Improvement in Itch Numerical Rating Scale (NRS) Score at Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)Time frame: Week 16
    • AddedPercent Change From Baseline in Total Eczema Area and Severity Index (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)Time frame: Baseline, Week 16
    • RemovedPercentage of Participants With a Itch Numerical Rating Scale (NRS) Score of ≥4-Points at Baseline who Achieve a ≥4-Point Reduction in Itch NRS Score From Baseline to Week 16 for Combo CohortTime frame: Baseline, Week 16
    • RemovedPercentage Change From Baseline in EASI Score for Combo CohortTime frame: Baseline, Week 16
    • RemovedPercentage of Participants Achieving EASI-90 for Mono CohortTime frame: Week 16
    • RemovedPercentage of Participants With a Itch NRS Score of ≥4-Points at Baseline who Achieve a ≥4-Point Reduction in Itch NRS Score From Baseline to Week 16 for Mono CohortTime frame: Baseline, Week 16
    • RemovedPercentage Change From Baseline in EASI Score for Mono CohortTime frame: Week 16
    • RemovedPercent Change from Baseline in Itch Numeric Rating Scale (NRS) for Mono CohortTime frame: Baseline, Week 16
    • RemovedChange from Baseline in Dermatology Life Quality Index (DLQI) for Mono CohortTime frame: Baseline, Week 16
    Interventions Arms added: Combo Cohort: Placebo + TCS·Combo Cohort: 250 mg Lebrikizumab + TCS·Mono Cohort: 250 mg Lebrikizumab·Mono Cohort: Placebo; arms removed: Lebrikizumab every 2 weeks (Q2W)·Lebrikizumab every 4 weeks (Q4W)·Lebrikizumab every 8 weeks (Q8W)·Escape Arm (Lebrikizumab Q2W)·Placebo
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06280716
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Apr 24, 2024
Primary completion
Sep 25, 2025
Completion
Jul 16, 2026
Results posted
Oct 16, 2026
Last update
Oct 16, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion